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INTRODUCTION
Vascular access (VA) events including stenosis and thrombo-
sis are major causes of VA failure with hemodialysis (HD).
Surveillance of VA is currently recommended because under-
dialysis due to the vascular access problem can be minimized,
and the rate of thrombosis can be reduced (1-3). Vascular access
blood flow (VABF) is one of the clinical predictors of steno-
sis and thrombosis and has been used for surveillance of VA
in most HD centers. Previous reports have shown that low
VABF (access flow rate less than 600 mL/min in arteriove-
nous grafts [AVGs] and less than 400 to 500 mL/min in arte-
riovenous fistulas [AVFs]) is a risk factor for vascular access
stenosis and thrombosis (1, 4-6). These reports also indicat-
ed that a sequential decrease in VABF (more than 25% over
4 months) can predict VA stenosis and thrombosis (5, 7, 8).
In these reports, however, VABF was a short-term predictor
of stenosis and thrombosis (almost within 3 months) (4, 5,
7, 9, 10). 
The early detection of stenosis and thrombosis and the early
correction of lesions have not been clearly demonstrated to
prolong VA survival. Tessitore et al. (6) reported that a higher
baseline VABF was the only variable associated with a favor-
able outcome for VA longevity. However, HD patients were
enrolled with various VA ages, and the study was not designed
to evaluate long-term predictors. In order to evaluate whether
early VABF may predict long-term VA patency, we performed
a prospective long-term observational study among patients
newly started on HD.
MATERIALS AND METHODS
Patient characteristics
A total of 57 patients at the Gachon University Gil Hospi-
tal outpatient dialysis center were included. They started HD
between January 1, 2005 and December 31, 2007, and all of
the patients had de novo VAs. Patients with maturation fail-
ure of VA were excluded from the study, as it was impossible
to measure VABF using the ultrasound dilution technique.
This study was approved by the institutional review board
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Early Vascular Access Blood Flow as a Predictor of Long-term 
Vascular Access Patency in Incident Hemodialysis Patients 
The long-term clinical benefits of vascular access blood flow (VABF) measurements
in hemodialysis (HD) patients have been controversial. We evaluated whether early
VABF may predict long-term vascular access (VA) patency in incident HD patients.
We enrolled 57 patients, of whom 27 were starting HD with arteriovenous fistulas
(AVFs) and 30 with arteriovenous grafts (AVGs). The patients’ VABF was measured
monthly with the ultrasound dilution technique over the course of the first six months
after the VA operation. During the 20.4-month observational period, a total of 40
VA events in 23 patients were documented. The new VA events included 13 cases
of stenosis and 10 thrombotic events. The lowest quartile of average early VABF
was related to the new VA events. After adjusting for covariates such as gender,
age, hypertension, diabetes, VA type, hemoglobin levels, body mass index, parathy-
roid hormone, and calcium-phosphorus product levels, the hazard ratio of VABF
(defined as <853 mL/min in AVF or <830 mL/min in AVG) to incident VA was 3.077
(95% confidence interval, 1.127-8.395; P=0.028). There were no significant rela-
tionships between early VABF parameters and VA thrombosis. It is concluded that
early VABF may predict long-term VA patency, particularly VA stenosis.
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of Gachon University Gil Hospital (#GIRBA 1780). All of
the patients were dialyzed with biocompatible membranes
(F5 or F6; Fresenius Medical Care AG, Bad Homberg, Ger-
many) three times per week using Fresenius 4008H (Frese-
nius Medical Care AG).
Vascular access characteristics
All of the permanent de novo VAs were actively used for
chronic HD three times per week. The time difference between
the VA operation and the first use of VA was at least six weeks
in AVFs and at least four weeks in AVGs. Baseline character-
istics, including the type of VA and its anatomic location, were
collected for all VAs starting HD (Table 1). 
Study design
This study was designed as a prospective cohort observa-
tional study. VABF was measured with the ultrasound dilu-
tion technique (Transonic Systems, Inc., Ithaca, NY, USA)
at one month intervals until six months after the VA opera-
tion. The measurement was performed within the first half-
hour of the dialysis session for each patient at a blood flow
rate of 250-300 mL/min (11, 12). Ultrafiltration was turned
off 3 min before the start of the measurements in order to avoid
the effect of hemoconcentration during the measurements. All
patients were monitored for VA events such as VA stenosis and
thrombosis. Patients who had physical findings of persistent
swelling of the arm, prolonged bleeding after needle withdraw-
al or altered characteristics of pulse or thrill in the outflow
vein also had their VABF measured, and they were referred for
angiography if their VABF was less than 600 mL/min in grafts
and less than 400 to 500 mL/min in fistulas (1).
Definitions
The endpoint of interest was the development of new VA
events at the follow-up examination. VA events included VA
stenosis, which was defined as a 50% or greater decrease in
luminal diameter, and thrombotic events on fistulography
or vascular operation (13). All VAs were monitored for the
occurrence of VA events until the last follow-up visit.
Data on the early VABF parameters, which we call the early
VABFs, were collected between the first use of VA up to six
months after the VA operation. When the VA events occurred
within the first six months, data were collected from the first
use of the VA to the time of the VA events. The early VABF
parameters consisted of the average, minimum, and initial
values of early VABF rates, and these were calculated from
the early VABFs. The initial value of VABF was defined as
the VABF measured at the first use of the VA.
Statistical analyses
The data are presented as medians (interquartile range) for
continuous variables and as proportions for categorical vari-
ables. Normally distributed data were analyzed with unpaired
t-tests; skewed data were analyzed with the Mann-Whitney
U test. The early VABF parameters were divided into the low-
est quartile and all other quartiles, according to the VA types.
Patients with AVF (n=27)
aVABF 
≥853 mL/min
(n=20)
aVABF
<853 mL/min
(n=7)
Parameters
Total patients
(n=57) P
Patients with AVG (n=30)
aVABF 
≥830 mL/min
(n=23)
aVABF
<830 mL/min
(n=7)
P
Male (%) 25 (43.9) 3 13 0.305 2 7 0.925
Age (yr) 54.0 (44.0-63.0) 59.0 (47.0-69.0) 51.0 (39.5-59.3) 0.293 63.0 (41.0-65.0) 52.0 (45.0-67.0) 0.980
Hypertension (%) 48 (84.2) 7 18 0.306 4 19 0.163
Diabetes (%) 30 (52.6) 4 8 0.432 4 14 0.860
Hemoglobin (g/dL)  10.7 (9.75-11.5) 10.2 (9.20-12.1) 10.9 (9.33-11.6) 0.912 11.1 (10.3-11.7) 10.7 (9.80-11.1) 0.606
PTH (mg/dL) 159 (86.2-321) 52.0 (17.2-163) 186 (126-420) 0.011 187 (126-708) 136 (62.6-290) 0.263
Calcium (mg/dL) 8.30 (7.65-9.25) 8.20 (7.40-9.50) 8.30 (7.85-9.28) 0.618 7.90 (7.00-9.10) 8.40 (7.50-9.30) 0.201
Phosphorus (mg/dL) 4.40 (3.65-5.25) 3.80 (3.10-5.30) 4.40 (3.85-4.85) 0.234 4.70 (3.80-5.50) 4.60 (3.40-5.60) 0.659
Ca×P (mg
2/dL
2) 36.9 (29.6-42.4) 32.8 (25.4-38.2) 37.2 (30.8-46.0) 0.158 37.1 (33.1-41.6) 37.1 (28.6-48.0) 0.980
Anti-platelet agents (%) 55 (96.5) 7 19 0.547 7 22 0.575
Body mass index (kg/m
2)  23.0 (21.2-26.3) 21.4 (19.9-32.4) 22.8 (20.9-24.2) 0.825 26.6 (23.6-31.7) 22.9 (21.3-27.2) 0.148
Previous catheter history (%) 46 (80.7) 6 16 0.738 5 19 0.517
Location of VA (%) 0.385 0.177
Left lower arm 46 (80.7) 7 15 6 18
Left upper arm 4 (7.0) 0 1 0 3
Right lower arm 7 (12.3) 0 4 1 2
Table 1. Demographics and other characteristics of subjects
Values are medians (interquartile ranges). 
AVF, arteriovenous fistula; AVG, arteriovenous graft; aVABF, average of early vascular access blood flow; PTH, parathyroid hormone; Ca×P, calcium
and phosphorus products.730 H.S. Kim, J.-W. Park, J.H. Chang, et al.
The event-free survival based on the early VABF parameters
was analyzed using the Kaplan-Meier method and tested using
the log-rank test. The hazard ratios between the early VABF
parameters and the development of vascular events were deter-
mined by univariate Cox-regression analysis. A multivariable
Cox-regression analysis then was performed to evaluate the
effects of the early VABF parameters, with adjustment for con-
founding variables. Covariates were assessed at the baseline
examination and included gender, age, hypertension, diabetes,
vascular access type, hemoglobin levels, body mass index,
parathyroid hormone (PTH), and calcium-phosphorus prod-
uct levels.
The analyses were conducted using SPSS for Windows ver-
sion 11.0 software (SPSS Inc., Chicago, IL, USA). P<0.05 was
considered to be statistically significant. 
RESULTS
The baseline demographics are listed in Table 1. The medi-
an age of the patients was 54.0 (44.0-63.0) yr, and the propor-
tion of male patients was 44%. The VA types included
AVFs in 27 patients and AVGs in 30 patients. About half of
the patients had diabetes mellitus, and most of the VAs were
located in the left lower arms. Anti-platelet agents were pre-
scribed to most of the patients.
The lowest quartiles of average early VABF rates were 853
mL/min in AVFs and 830 mL/min in AVGs (Table 2). We
compared the lowest quartile of average early VABF with the
other quartiles according to the VA types (Table 1). There were
no significant differences between the lowest quartile group
and the other quartile groups in clinical factors such as gen-
der, age, hypertension, diabetes, hemoglobin levels, calcium-
phosphorus product levels, anti-platelet agents, body mass
index, previous catheter history, and location of VA, although
the baseline PTH levels were slightly lower in the lowest quar-
tile group with AVF. Two surgeons created all of the VAs in
our study. Surgeon A operated from January to July 2005 and
Surgeon B operated from August 2005 to December 2007,
and there was no significant difference in the proportion of
patients in the lowest quartile group and the other quartiles
between the two surgeons (P=0.711 in AVF, P=0.847 in
AVG). None of the enrolled patients had outflow tract obstruc-
tion.
A total of 40 VA events in 23 patients were documented
throughout the total observational period (0.404 events/
patient-year). During the 20.4±10.6 month observation,
six patients were discontinued from follow-up: four patients
died, and two patients received renal transplantation. On 15
patients, fistulography was performed for screening VA mal-
function. Eleven cases were identified based on the low level
of VABF using the ultrasound dilution technique, and four
cases were identified from the abnormal physical examina-
tion findings. Six cases showed fistulographic stenoses that
were located at the anastomic sites or juxta anastomic proxi-
mal veins in AVF, and seven cases showed stenoses that were
located at the venous anastomic sites or the arterial anastom-
ic sites in AVG. Two cases had mild stenosis (less than 50%
in luminal diameter), and had no further intervention. Ten
cases of thrombotic events showed abnormal findings such
as no thrill and no pulsation of VA, and all of them received
thrombectomy. In summary, the new VA events included 13
cases of stenosis, and 10 cases of thrombosis. 
Within 12 months after the VA operation, the number of
the new VA events was 15 out of a total of 23 events (65%).
The mean time between the VA operation and the new VA
events was about 10 months in the 23 patients who experi-
enced the VA events (Fig. 1).
Risk factors for the development of the new vascular
access events
We analyzed the unadjusted and adjusted hazard ratios for
AVF, arteriovenous fistula; AVG, arteriovenous graft; VABF, vascular access blood flow.
AVF (n=27)
Parameters
25 percentile 50 percentile 75 percentile
AVG (n=30)
25 percentile 50 percentile 75 percentile
Average of early VABFs (mL/min) 853 1,128 1,550 830 1,104 1,468
Minimum of early VABFs (mL/min) 740 880 1,290 798 985 1,308
Table 2. Early vascular access blood flow parameters according to vascular access types
C
u
m
u
l
a
t
i
v
e
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
t
h
e
 
f
i
r
s
t
v
a
s
c
u
l
a
r
 
a
c
c
e
s
s
 
e
v
e
n
t
s
25
20
15
10
5
0
Fig. 1. Cumulative incidence of new vascular access events.
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early VABF parameters associated with the development of
the new VA events (Table 3). The lowest quartile of average
early VABF (<853 mL/min in AVF, <830 mL/min in AVG)
was associated with the development of total VA events after
adjustment for gender, age, hypertension, diabetes, vascular
access type, hemoglobin levels, body mass index, parathyroid
hormone, and calcium-phosphorus product levels (hazard
ratio [HR], 3.077; 95% confidence interval [CI], 1.127-8.395;
P=0.028). HR for the lowest quartile of minimum early VABF
for the risk of VA events was 2.652, but this was not statis-
tically significant. The initial value of VABF was not related
to the new VA events. The lowest quartiles of the average and
minimum values obtained from the early VABFs were signifi-
cantly associated with the development of the new VA steno-
sis after adjustment of covariates. However, the unadjusted
and adjusted hazard ratios for all of the parameters associat-
ed with the development of the new thrombosis were not
statistically significant.
VA patency until the new vascular access events
After the stratification of groups according to VA types,
patients with the lowest quartile of average early VABF had
worse total VA event-free survival rates than those in the other
quartiles (P=0.002). Patients with the lowest quartile of aver-
age values had also lower stenosis-free survival probabilities
than those in other quartiles (P=0.003) (Fig. 2). However,
there was no significant relationship between thrombosis-
free survival and the lowest quartile of average early VABF
(data not shown). 
Total event-free survival and stenosis-free survival were also
significantly worse in patients with the lowest quartiles of
minimum early VABF (P=0.013 and P=0.011, respectively);
this was similar to the results obtained for patients in the
lowest quartiles of average early VABF. However, thrombo-
sis-free survival did not show a significant difference between
the lowest quartile and other quartiles.
Gender, age, hypertension, diabetes, vascular access type, hemoglobin levels, body mass index, parathyroid hormone levels and Ca×P values were
included as *covariates; 
�
Parameters were measured during the first 6 month period. Hazard ratios (HR) are calculated for being in the lowest quartile
compared with not being in the lowest quartile for the parameters indicated above. 
CI, confidence interval; AVF, arteriovenous fistula; AVG, arteriovenous graft; BMI, body mass index; VA, vascular access; VABF, vascular access
blood flow.
Parameters PP P
Age, sex-adjusted
HR (95% CI)
All adjusted HR
(95% CI)*
HR (95% CI)
Risk of total VA events (stenosis+thrombosis)
Average of early VABFs
� 3.361 (1.414-7.988) 0.006 2.690 (1.020-6.579) 0.030 3.077 (1.127-8.395) 0.028
Minimum of early VABFs
� 2.859 (1.208-6.769) 0.017 2.371 (0.984-5.714) 0.054 2.652 (0.969-7.260) 0.058
Risk of new VA stenosis
Average of early VABFs
� 4.525 (1.502-13.63) 0.007 3.759 (1.201-11.77) 0.023 5.090 (1.471-23.74) 0.012
Minimum of early VABFs
� 2.884 (0.938-8.874) 0.064 3.139 (1.029-9.578) 0.044 4.384 (1.146-16.77) 0.031
Risk of new VA thrombosis
Average of early VABFs
� 2.128 (0.516-8.777) 0.296 1.663 (0.381-7.252) 0.498 1.425 (0.232-8.771) 0.702
Minimum of early VABFs
� 1.860 (0.454-7.624) 0.389 1.559 (0.362-6.707) 0.551 1.794 (0.203-15.88) 0.599
Table 3. Association between early VABF and the new VA events
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Fig. 2. Stenosis-free survival according to the average vascular access blood flow (VABF): (A) Stenosis-free survival in patients with arteri-
ovenous fistulae (AVF) and (B) in patients with arteriovenous grafts (AVG). The dotted lines represent the patients in the lowest quartile of
average early VABF (<853 mL/min in AVF and <830 mL/min in AVG), and the solid lines represent the patients in the other quartiles (P=0.003).
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Subgroup analysis in patients with all of the vascular events
Ten patients (4 in AVFs and 6 in AVGs) had 2 or more
events, and 4 patients had 3 or more events during the obser-
vational period. Six patients had new VA events within 6
months of the VA operation. Vascular access survival could
not be analyzed because only 2 patients had vascular access
failures. 
DISCUSSION
The aim of the study was to evaluate whether early VABF
can predict long-term VA patency in incident HD patients.
We found that low levels of average and minimum early VABF
may increase the risk of the development of total VA events,
especially with regard to the new VA stenosis, and can pre-
dict poor event-free survival or stenosis-free survival proba-
bilities. Thus, patients with low average or minimum levels
of VABF within six months after the VA operation should be
monitored more carefully and frequently.
Several reports have shown that a low VABF or a sequen-
tial decrease in VABF increases the risk of VA stenosis and
thrombosis within a short-term period (1, 4, 5, 7, 9, 10). Pre-
vious trials studying the association between VABF and VA
longevity enrolled HD patients with a mean VA age of more
than 18 months (6). In contrast, our current study enrolled
incident HD patients with de novo VAs and evaluated the
clinical usefulness of early VABF parameters as long-term pre-
dictors of VA stenosis and thrombosis. 
VABF measured up to six months after the VA operation
was defined as early VABF. Practically, the maturation peri-
od is four to six weeks after the operation for AVFs and two
or more weeks for AVGs. By our definition, early VABF in-
cluded three to four values of VABF from every patient because
we measured VABF on a monthly basis. These serial data could
be more representative of VA patency than a single measure-
ment of VABF. In addition, according to the natural history
of VA, the VA patency rates rapidly decrease during the early
period, and loss of VA patency occurs at a rate of 25% within
9 months (14). Moist et al. (15) reported that a longer time
between graft creation and study enrollment is associated
with a decreased risk of graft thrombosis. Thus, VA surveil-
lance should be started right after the first use of the VA, and
these early VABFs could have a more important role than
VABF values from the late period. This is another reason that
we enrolled only patients with de novo VAs.
The average and minimum early VABF values were signif-
icant predictors of event-free survival of VAs in our study.
The initial VABF parameters displayed a wide range of val-
ues and were not useful in predicting the VA events, as the
early values of VABF could change after the first use of the VA.
The current data demonstrated that early VABF parameters
were not significantly associated with VA thrombotic events.
In contrast, other reports have shown that a low VABF has also
been associated with an increased risk for VA thrombosis (5,
9, 16-18). There are several possible explanations for this dis-
crepancy. First, most of the thrombotic events may follow VA
stenoses, and some of the patients with a VA stenosis in our
study might have been treated before thrombosis occurred.
In addition, anti-platelet agents were prescribed for most of
the enrolled patients; this could have reduced the development
of thrombosis (15, 19).
There were some limitations to our study. First, the sam-
ple size was not large enough to stratify the subgroups. How-
ever, we followed up patients for durations that were longer
than used in any of the previous clinical trials (4, 7, 10, 17)
in order to overcome the effects of a relatively small number
of patients. In addition, we enrolled incident HD patients
with de novo VAs in order to avoid a lead-time bias. Second,
overall VA patency could not be analyzed because there were
few VA failures in the enrolled patients. We considered pri-
mary patency as the end point, which could be viewed as a
surrogate indicator of overall VA patency. A large-scale trial
is needed to clarify this potential relationship between early
VABF parameters and overall VA survival. Third, several reports
revealed that VABF measurement using the ultrasound dilu-
tion technique allows non-invasive continuous monitoring
of VA and has good accuracy and reproducibility (1, 11, 12,
20-22). However, the ultrasound dilution technique method
cannot be used until the patient is using VA for HD; thus
we could not evaluate information on VA maturation. 
Some reports showed that the early detection of stenosis
and thrombosis and the early correction of lesions cannot pro-
long VA overall survival (1, 2, 23). In contrast, other reports
demonstrated that well-programmed regular surveillance not
only fosters the ability to detect VA events, but also prevents
the morbidity and mortality associated with the failure to
detect VA dysfunction (1, 3). We showed that low values of
early VABF parameters may predict VA events, especially
stenosis in incident hemodialysis patients. This suggests that
we should focus on the high risk group with low values of
early VABF parameters for effective surveillance of VA patency. 
In summary, we found that low values of early VABF param-
eters were associated with the development of VA events,
especially VA stenosis, and poor event-free survival or steno-
sis-free survival probability. This suggests that some of the
VABF parameters in the early period of VA creation may pre-
dict long-term VA patency in incident HD patients. These
results indicate that some groups of patients with low values
of early VABF parameters should be monitored more care-
fully to prevent VA events. 
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